Vaccine strategy  SIgA anti-FIV-p241 SIgA anti-HIV gp1202 SIgG anti-HIV gp1202 Week 2 Week 4 Week 6 Week 8 Week 8 Week 8 IM 1:2,400 1:1,200 1:300 1:300 Negative 1:9,600 IM Negative Negative Negative Negative Negative3 Not tested IM+ A(1-7) Negative 1:300 1:300 1:1,200 1:9,600 Not tested Topical gel only 1:1,200 Negative 1;300 Negative Negative3 Negative 0.1 mg A(1-7) 1;300 1:300 1:4,800 1:1,200 Negative Negative 0.2 mg A(1-7) 1:300 1:1,200 1:2,400 1:300 1:4,800 1:76,800 0.3 mg A(1-7) 1:19,200 1:2,400 1:300 Negative 1:2,400 1:4,800 0.4 mg A(1-7) 1:4,800 1:19,200 1:19,200 1:4,800 1:9,600 1:2,400 5.0 mg A(1-7) Negative Negative Negative Negative Negative Negative 7.5 mg A(1-7) Negative Negative Negative Negative 1:1,200 Negative 10.0 mg A(1-7) Negative 1:4,800 Negative Negative 1:38,400 Negative

1Undiluted was the lowest dilution tested with an elution factor of 300-fold. 21:4 was the lowest dilution tested with an elution factor of 300-fold. 3Sample tested was from week 6.

Table 3: Vaginal secretory antibody titers.